CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 49 enrolled
Drug / intervention
Milnacipran +1 moredrug
Likely dose
Milnacipran 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01207453
NCT01207453Phase 4Completed

Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis

Brigham and Women's Hospital·interventional·Posted Sep 23, 2010·Updated Nov 17, 2014

In Brief

A Phase 4 clinical trial evaluating Milnacipran and Placebo for Arthritis, Rheumatoid. Completed, enrolled 49 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether milnacipran reduces widespread, non-joint pain in patients with rheumatoid arthritis (RA). The investigators will conduct a double-blind randomized crossover trial in subjects with RA to test the hypothesis that milnacipran improves widespread, non-joint pain. The investigators will also use data from the trial to determine whether response to milnacipran is associated with pain-modulating mechanisms from the central nervous system. The investigators hypothesize that response to milnacipran will be greater among patients with impaired central pain mechanisms than among patients with intact central pain modulating mechanisms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 23, 2010
Enrollment StartJan 1, 2011
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 15.8 years ago

Interventions

Milnaciprandrug

Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.

Placebodrug